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ABSTRACT 
There is a common perception that complex undefined diseases manifested with diverse 
combination of symptoms and a difficult clinical diagnosis have a possible common 
physiological mechanism of disease production.
Physical or cognitive fatigue, widespread pain without arthritis, sleep, mood and autonomic 
disturbances as well as multiple intolerance involving drug, food, chemical agents, 
electromagnetic fields or other environmental factors may be included in this category.
Along last three decades, the existence of central sensitivity as a well established common 
pathogenic mechanism involved in abnormal symptom development emerged in diverse areas 
as pain, fatigue, food and environmental intolerance, as well as in the global chronic disease 
epidemic. The common fact of all of these disorders is a deregulation of the central control 
mechanisms at the limbic brain system. This may relate to amplification of pain and fatigue 
perception and disturbance of environmental tolerance and control of circadian rhythms and 
mood.  This deregulation causes amplification of central somatosensory perception, but also a 
decrease of nociceptive inhibitory outputs. The final result is a chronic condition with central 
hyperexcitability and systemic disabling symptoms highly difficult to manage.
This article comments on the current significance to evaluate central sensitization symptoms 
and to consider these mechanisms in the development of complex diseases, as well as in the 
global chronic disease epidemic. We propose to include central sensitization to structuring 
a multidisciplinary concept addressed to improve scientific comprehension and clinical 
management of diseases, as well as future research directions on this field.
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Introduction
During the last three decades, most clinicians 
attending patients with complex undefined 
diseases have perception of a possible common 
involvement between different medical separated 
entities that share diverse combination of 
symptoms [1]. Those included physical or 
cognitive fatigue, widespread pain without 
arthritis, sleep, mood and autonomic disturbances 
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up to 80% of cases in fibromyalgia and chronic 
fatigue syndrome, thus suggesting a common 
physiopathological mechanism [17]. In addition 
to FM and CFS, other entities appeared as a co-
morbid phenomenon in the natural FM-CFS 
course of disease [18]. Thus, the incidence of 
migraine, irritable bowel syndrome, temporo-
mandibular disorders, restless leg syndrome, 
chronic pelvic pain, interstitial cystitis, 
sicca syndrome, chemical or environmental 
intolerances and others was described as highly 
related to either FM or CFS [9,19,20].
Another objective factor in patients with FM or 
CFS was the frequent appearance of symptoms 
related to intolerance to drugs, mainly active 
psychotropic, analgesic and anti-inflammatory 
drugs [21]. But this intolerance was amplified to 
food compounds or other multiple environmental 
factors [22]. Thus, these patients tend to avoid 
consumption of alcohol, caffeine, lactose, 
fructose, gluten or fat-rich nutrients because of 
a clear intolerance [23]. They were sensitive to 
environmental temperature or humidity changes 
[24], as well as to intense light or high-level of 
noise [25]. This reactivity was also amplified to 
the loss of tolerance to environmental irritant 
chemicals such as cosmetics, fragrances, chloride 
or phosphate biocides, solvents or hydrocarbon 
compounds that should be avoided [26,27].
The sensitivity to electromagnetic-fields (EMF) 
is the last element added to this series [28]. In 
this case, the subject develops symptoms when 
exposed to low intensity EMF of different origin 
in the spectrum of non-ionizing waves (wi-fi, 
mobile phones, computer screens, antennas). 
Those symptoms clearly improve when the 
subject avoids those EMF exposures [29].
The emergence of central sensitivity in the past 
30 years linked to various complex undefined 
diseases may be associated with the global 
chronic disease epidemic [30].
The multiplicity of inciting agents that can 
get worse the course of this diseases leads to 
consider the concept of Exosome. This includes 
all these different physical, chemical or biological 
factors that may contribute from outside the 
human body in a cumulative and synergistic 
manner [31,32]. This concept also relates to 
the Endosome, considering changes induced in 
intestinal or visceral microbiota and also mood 
and stress-related changes [33]. Exposome 
would be the sum of exo and endosome factors, 
considering all their global and summation effect. 
The exposome may target a sensitive subject in a 
as well as multiple intolerances involving drug, 
food, chemical agents, electromagnetic fields or 
other environmental factors [2-4].
The common fact of all of them is a deregulation 
of the central control mechanisms related to 
pain and fatigue perception, environmental 
tolerance and control of circadian rhythms [5,6]. 
This deregulation causes amplification of central 
somatosensory perception and development of 
chronic disabling symptoms [7].
Although this context is clear at clinical level 
and symptom presentation is quite similar 
in most patients, the absence of biological or 
morphological specific markers has supposed a 
difficulty to categorize these entities [4]. At the 
beginning, a persistent claim against to recognize 
these specific entities appeared, just suggesting 
to be in front of a somatoform-like paradigm 
without objective basis of disease [8,9]. However, 
based on epidemiological and clinical evidence, 
and the existence of a common physiological 
underlying mechanism of disease, a progressive 
scientific recognition has been established by 
diverse Committees and Medical Associations 
and case-diagnostic criteria appeared in some of 
these entities [2,10,11].
Thus, Chronic Fatigue Syndrome (CFS) was 
clinically defined in 1988 by Holmes et al. [12] 
after a task-force from NIH, USA. Pathological 
persistent physical and cognitive fatigue that does 
not improve at rest and exercise intolerance with 
post-exertion malaise is hallmark of this disease. 
Along the same period, the American College of 
Rheumatology defined the first clinical criteria 
for Fibromyalgia (FM) based on pain perception 
at pre-defined trigger points [13]. These criteria 
were modified on 2010 with a most waste and 
systemic inclusion of symptoms, also defining the 
intensity of involvement with the Widespread 
Pain Index (WPI) and the Symptom Severity 
scale (SSs) [14].
Those entities were recognized as specific diseases 
by the World Health Organization in 1990. In 
both cases, the initial criteria evolved to other 
more extensive, recognizing that fibromyalgia 
is not only a disturbance of pain perception or 
chronic fatigue is not just an exercise intolerance, 
being both entities characterized with a 
clear systemic and diffuse involvement with 
multiplicity of concomitant symptoms [15,16].
One of the most relevant facts that appeared 
along the natural course of disease is the high 
level of co-morbidity between them, achieving 
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subclinical appearance for time (masking), until 
this subject lost his biological tolerance capacity 
and symptoms appear (clinical phase) [34]. 
Claudia Miller et al. [35] generated the concept 
of toxic-induce lost of tolerance to define when 
central sensitization mechanisms appeared in 
front of persistent environmental low- level toxic 
exposure. Intolerance to food, drugs, chemicals, 
heat and environment factors may inactivate the 
anti-aging gene that is linked to mitocondrial 
apoptosis in the brain and other tissues [36].
Central Sensitization
The common mechanism that explains the 
multiplicity of symptoms in front of diverse 
exposure in susceptible subjects is central 
sensitization [5,6,37]. This is a neurologic 
inflammatory-based mechanism located in the 
limbic system that includes mid-brain associated 
structures such as the hypothalamus, hypophysis, 
amygdala, thalamus and cortical projections 
[38,39]. When a peripheral stimulus is generated 
in a susceptible individual, the conduction 
sensory system amplifies it at the dorsal roots 
(spinal hyperexcitability). This amplified stimuli 
still increases in power when received in the 
thalamus and projected to the limbic system and 
cortex. The result is an expanded input in the 
somatosensory brain with high-level nociceptive 
perception [7]. A central amplification occurs 
enhancing the pain response to noxious stimuli 
in amplitude, duration and spatial extent, 
establishing stronger brain memory [40]. Thus, 
sensory- afferent signals overwhelm the body’s 
ability to filter them. The result is the generation 
of diverse abnormal symptoms such as pain, 
fatigue, insomnia, irritability or confusion. In 
addition to this increased input, the system 
does not produce adequate negative outputs to 
decrease or inhibit the stimulus. Since there is 
no decreasing of anti-nociceptive pathways, the 
response tends to be persistent and produces 
symptom maintenance [41].
This global mechanism generates an abnormal 
and progressively increased response over time, 
similar to the epilepsy wind-up or kindling 
phenomenon with a final additive effect [42,43]. 
This limbic abnormal amplification response 
was first described in neuropathic pain pathways 
[44,45], but later also corroborated for physical 
and cognitive fatigue [46] and chemical [47,48] 
or EMF sensitivity [28]. So, different external 
stimuli in nature (physical, chemical, biological 
or phychological), may generate a common 
phenomenon of abnormal limbic deregulation 
and a variety of amplified symptoms, that set 
up the Central Sensitivity spectrum of response 
(Table 1) [1,10,48]. In this process, anti-aging 
genes inactivation by environment factors may 
have a relevant role [30,49,50].
Evidently, development of CS mechanisms in 
a subject is compatible with the coexistence of 
other pathogenic mechanisms such as infection, 
autoimmune, auto- inflammatory, endocrine or 
autonomic deregulation disorders [4,7,9,18,51]. 
In fact, the sum of all of them may be additive 
and synergistic [5,6]. CS frequently appears after 
the onset of a specific medical entity, for instance 
in multiple sclerosis [52] or rheumatoid arthritis 
[53].
Symptoms that may appear in CS are diverse 
in nature and intensity, reflecting a systemic 
deregulatory failure [1,54]. Table 1 describes 
the most frequent symptoms of CSS. Usually, 
at one time, the subject with CSS may share 
5 to 8 different symptoms, being the clinical 
scenario diverse, pathomorphic and difficult to 
evaluate [1,2]. One of the peculiar characteristics 
in CS is the worsening of symptoms when the 
Table 1: Main reported symptoms in the central sensitization clinical spectrum.
Pain (either diffuse of focal, persistent, oscillating)
• Musculoskeletal
• Cephalalgia
• Abdominal
• Pelvic-Gynecological
Fatigue
• Physical (exercises intolerance)
• Cognitive (short-term memory, attention, concentration)
• Post exertional malaise
- Skin Itching- Burning
- Confusion
- Tremor - Myoclonia
- Blurry Vision
- Dry Eye - Dry Mouth - Skin Dryness
- Odynophagia
- Cough
- Dysphonia and Fonastenia
- Food Intolerance
- Nauseas
- Diarrhea
- Postural Hypotension-Tachycardia
- Dysthermia-Sweating
- Paresthesias
- Muscle Stiffness - Cramps
- Insomnia – Diurnal Somnolence
- Sleep Apneas
- Anxiety- Irritability- Stress intolerance
- Dysthymia - Depression
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sensitization mechanism is over. For instance, 
subjects with MCS clearly develop symptoms 
when exposed to low-dose of chemical inciting 
products [48] or subjects with EMF sensitivity 
worsen when are exposed near to EMF at lo-
intensity range [28]. Abnormal physical or 
neurocognitive fatigue increase when subject 
surpasses his exercise tolerance, a situation that 
usually coincides with the anaerobic exercise 
threshold [55]. Pain in Fibromialgia develops 
inadequately at low-level of activity and local 
pressure of sensitive areas, but is abnormally 
prolonged at rest [3].
Therefore, the CS spectrum of disease is large, 
and includes more than 50 different diseases 
where CS mechanisms may play a partial or 
significant role [1,19]. Table 2 reflects the most 
usual clinical entities proposed to be almost 
partially affected by CS mechanisms [6,35].
Criteria for Central Sensitivity have been defined 
when coexist more than one specific disease and 
different areas of hypersensitivity affected in this 
large spectrum [10,54].
  The relevance to consider central 
sensitization mechanisms
When evaluating patients with a diversity of 
non-explained symptoms or when they have 
already configured one or more CS specific 
diseases, the possibility that some of those 
symptoms to be mediated by CS mechanisms is 
relevant [5,6,19]. This is due to the implication 
of a peculiar scenario of disease development 
with multiplicity of clinical manifestations and 
a different therapeutic response [54]. Therefore, 
in the management of patients with CS, 
multidisciplinary approach and personalized care 
medicine is necessary [17,56-60].
For instance, we should not expect to find 
specific biochemical or structural changes 
explaining this disease [4,61,62]. There is no 
correlation between the intensity of biochemical 
inflammatory response and the clinical 
symptoms [5,63]. In addition, we should 
differentiate this CS neurological mechanism 
to other of somatophorm origin [9,11]. 
Because of this difficulty to approach patients’ 
symptoms, in the initial symptom evaluation 
of CS disorders it has been proposed to use 
the short-form central sensitization inventory 
[64,65] and manage these patients in medical 
specialized areas [37,44]. Similarly, the response 
to treatment is only symptomatic and at low-
intensity level [4,10,56]. Thus, just multi-
factorial multidisciplinary approaches are able to 
get some symptom improvement in CS diseases. 
In general, pharmacologic symptom treatment 
should be individualized and complemented 
by avoidance of inciting agents, personalized 
physical exercise, dietary and environmental 
changes, psycho-educative adaptation support 
and cognitive behavioral therapy [66-68].
The oscillating course of CS also contributes 
to difficult interpretation of symptoms. Patient 
expectations usually differ from that possible 
to accomplish in CS disease management. This 
may cause dissatisfaction either for the patient, 
but also for the doctor and the health system 
[35,68,69].
Conclusion
Current scientific knowledge concerning 
mechanisms of disease in central sensitivity is 
clear and consistent, opening an opportunity 
to better understand these complex diseases 
involved in this clinical scenario [2,4,37,41,45]. 
Consequently, we suggest a better doctor 
consideration in relation to ascertain this 
mechanistic explanation and specific rules 
of CS disease development. This may allow 
to structuring a more precise pathogenic 
multidisciplinary CS concept [70]. This will 
apply to improve the practical management on 
these complex diseases and offers a therapeutic 
target as well as future research opportunities 
[5,45]. On this sense, possibilities to modify 
the anti- aging genes [71] and introduce 
neuromodulation strategies [72] may be of 
interest in CS management. This paradigm 
should be necessarily projected and reflected on 
Table 2: Most usual clinical entities proposed to be involved in central sensitization 
mechanisms.
• Fibromyalgia • Seasonal affective disorder
• Chronic fatigue syndrome • Traumatic stress disorder
• Multiple chemical sensitivity • Post-depression syndrome
• Electrohypersensitivity • Primary dysmenorrhea and Endometriosis
• Myofascial pain syndrome • Restless leg syndrome
• Migraine headache • Periodic limb movement disorder
• Tension-type headache • Non–celiac gluten intolerance
• Burning mouth syndrome • Irritable bowel syndrome
• Atypical odontalgia • Intersticial-Irritative Cystitis
• Temporomandibular disorder • Histaminosis
• Eye-mouth dry syndrome • Attention deficit hyperactivity
• Visceral Pain Sensitivity Sd • Vulvodynia/vulvar/vestibulitis Sd
• Complex regional Pain Sd • Autism
• Tinnitus • Postural tachycardia Sd (POTS)
• Sleep-Apnea • Reflex sympathic algodistrophy (Sudeck)
• Raynaud (idiopatic) • Idiopathic dysthermia
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a better explanation of disease to the patient and 
may contribute to improve the patient-doctor 
relationship on this field, as well as a better CS 
patient follow-up in specialized areas.
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